The age of cancer: Telomeres, checkpoints, and longevity

Journal of Clinical Investigation

Volumn 111, Issue 7, 2003, Pages

  DePinho, Ronald A ^a   Wong, Kwok Kin ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; TELOMERASE;

AGING; CANCER; CANCER CONTROL; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL RESEARCH; CONFERENCE PAPER; DISEASE COURSE; GENETIC STABILITY; HEART DISEASE; HUMAN; HUMAN GENOME; INFLAMMATION; LONGEVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE;

ADOLESCENT; ADULT; ANIMALS; CHILD; HUMANS; INFLAMMATION; MICE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; TELOMERE;

EID: 0037380710     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. 2002. Cancer facts and figures 2002. American Cancer Society. Atlanta, Georgia, USA. 1-14.
2. 2002. A profile of older Americans: 2002. US Department of Health and Human Services, Administration on Aging. Washington, DC, USA. 1-14.
3. Anisimov, V.N. 2001. Mutant and genetically modified mice as models for studying the relationship between aging and carcinogenesis. Mech. Ageing Dev. 122:1221-1255.
4. Naf, D., Krupke, D.M., Sundberg, J.P., Eppig, J.T., and Bult, C.J. 2002. The Mouse Tumor Biology Database: a public resource for cancer genetics and pathology of the mouse. Cancer Res. 62:1235-1240.
5. Maser, R.S., and DePinho, R.A. 2002. Connecting chromosomes, crisis, and cancer. Science. 297:565-569.
6. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
7. Jackson, A.L., and Loeb, L.A. 1998. On the origin of multiple mutations in human cancers. Semin. Cancer Biol. 8:421-429.
8. Turker, M.S. 1998. Estimation of mutation frequencies in normal mammalian cells and the development of cancer. Semin. Cancer Biol. 8:407-419.
9. Knudson, A.G. 2001. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer. 1:157-162.
10. Sherr, C.J., and DePinho, R.A. 2000. Cellular senescence: mitotic clock or culture shock? Cell. 102:407-410.
11. Atkin, N.B. 1989. Solid tumor cytogenetics. Progress since 1979. Cancer Genet. Cytogenet. 40:3-12.
12. von Hansemann, D. 1890. Uber asymmetrische Zellteilung in Eithelkrebsen und deren biologische Bedeutung. Virchows Arch. Path. Anat. 119:299-326.
13. Boveri, T. 1914. Zur Frage der Entstebung Maligner Tumoren. Gustav Fischer. Jena, Germany. 64 pp.
14. Muller, H.J. 1927. Artificial transmutation of the gene. Science. 46:84-87.
15. Muller, H.J. 1938. The remaking of chromosomes. Collecting Net. 13:181-198.
16. McClintock, B. 1941. The stability of broken ends of chromosomes in zea mays. Genetics. 26:234-282.
17. Greider, C.W. 1998. Telomerase activity, cell proliferation, and cancer. Proc. Natl. Acad Sci. U. S. A. 95:90-2.
18. Harley, C.B., Futcher, A.B., and Greider, C.W. 1990. Telomeres shorten during ageing of human fibroblasts. Nature. 345:458-460.
19. Hastie, N.D., et al. 1990. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 346:866-868.
20. Allsopp, R.C., et al. 1992. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 89:10114-10118.
21. Chadeneau, C., Hay, K., Hirte, H.W., Gallinger, S., and Bacchetti, S. 1995. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 55:2533-2536.
22. Bodnar, A.G., et al. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:349-352.
23. Hahn, W.C., et al. 2002. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 22:2111-2123.
24. Kipling, D., and Cooke, H.J. 1990. Hypervariable ultra-long telomeres in mice. Nature. 347:400-402.
25. Martin-Rivera, L., Herrera, E., Albar, J.P., and Blasco, M.A. 1998. Expression of mouse telomerase catalytic subunit in embryos and adult tissues. Proc. Natl. Acad. Sci. U. S. A. 95:10471-10476.
26. Broccoli, D., Godley, L.A., Donehower, L.A., Varmus, H.E., and de Lange, T. 1996. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation oftelomerase RNA with cell proliferation. Mol. Cell. Biol. 16:3765-3772.
27. Greenberg, R.A., Allsopp, R.C., Chin, L., Morin, G.B., and DePinho, R.A. 1998. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene. 16:1723-1730.
28. Blasco, M.A., et al. 1997. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 91:25-34.
29. Lee, H.W., et al. 1998. Essential role of mouse telomerase in highly proliferative organs. Nature. 392:569-574.
30. Rudolph, K.L., et al. 1999. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell. 96:701-712.
31. Chin, L., et al. 1999. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 97:527-538.
32. Counter, C.M., et al. 1992. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1921-1929.
33. Rudolph, K.L., Millard, M., Bosenberg, M.W., and DePinho, R.A. 2001. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28:155-159.
34. Chang, S., Khoo, C.M., Naylor, M.L., Maser, R.S., and DePinho, R.A. 2003. Telomere-based crisis: functional differences between relomerase activation and ALT in tumor progression. Genes Dev. 17:88-100.
35. Armitage, P., and Doll, R. 1954. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer. 8:1-12.
36. Renan, M.J. 1993. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog. 7:139-146.
37. Artandi, S.E., et al. 2000. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 406:641-645.
38. O'Hagan, R.C., et al. 2002. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell. 2:149-155.
39. Nishizaki, T., et al. 1997. Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer. 19:267-272.
40. Buerger, H., et al. 1999. Comparative genomic hybridization of ductal carcinoma in situ of the breast: evidence of multiple genetic pathways. J. Pathol. 187:396-402.
41. Al-Mulla, F., Keith, W.N., Pickford, I.R., Going, J.J., and Birnie, G.D. 1999. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer. 24:306-314.
42. Gray, J.W., and Collins, C. 2000. Genome changes and gene expression in human solid tumors. Carcinogenesis. 21:443-452.
43. Tang, R., Cheng, A.-J., Wang, J.-Y., and Wang, T.-C.V. 1998. Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. Cancer Res. 58:4052-4054.
44. O'Sullivan, J.N., et al. 2002. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet. 32:280-284.
45. Gisselsson, D., et al. 2001. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc. Natl. Acad. Sci. U. S. A. 98:12683-12688.
46. Mitchell, J.R., Wood, E., and Collins, K. 1999. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 402:551-555.
47. Vulliamy, T., et al. 2001. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 413:432-435.
48. Rudolph, K.L., Chang, S., Millard, M., Schreiber-Agus, N., and DePinho, R.A. 2000. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science. 287:1253-1258.
49. de Lange, T. 1994. Activation of telomerase in a human tumor. Proc. Natl. Acad. Sci. U. S. A. 91:2882-2885.
50. Foley, K.P., and Eisenman, R.N. 1999. Two MAD tails: what the recent knockouts of Mad1 and Mxil tell us about the MYC/MAX/MAD network. Biochim. Biophys. Acta. 1423:M37-M47.
51. Kitada, T., Seki, S., Kawakita, N., Kuroki, T., and Monna, T. 1995. Telomere shortening in chronic liver diseases. Biochem. Biophys. Res. Commun. 211:33-39.
52. Miura, N., et al. 1997. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet. 93:56-62.
53. Urabe, Y., et al. 1996. Telomere length in human liver diseases. Liver. 16:293-297.
54. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell. 81:323-330.
55. Debbas, M., and White, E. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7:546-554.
56. Morgenbesser, S.D., Williams, B.O., Jacks, T., and DePinho, R.A. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 371:72-74.
57. Symonds, H., et al. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78:703-711.
58. Kim, N.W., et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011-2015.
59. Blasco, M.A., Rizen, M., Greider, C.W., and Hanahan, D. 1996. Differential regulation of telomerase activity and telomerase RNA during multistage tumorigenesis. Nat. Genet. 12:200-204.
60. Greenberg, R.A., et al. 1999. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell. 97:515-525.
61. Hahn, W.C., et al. 1999. Creation of human tumour cells with defined genetic elements. Nature. 400:464-468.
62. Chin, L., and DePinho, R.A. 2000. Flipping the oncogene switch: illumination of tumor maintenance and regression. Trends Genet. 16:147-150.
63. Kamijo, T., et al. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91:649-659.
64. Pomerantz, J., et al. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:713-723.
65. Mukherjee, B., Morgenbesser, S.D., and DePinho, R.A. 1992. Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. Genes Dev. 6:1480-1492.
66. Schreiber-Agus, N., et al. 1998. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature. 393:483-487.
67. Alland, L., et al. 1997. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature. 387:49-55.
68. Serrano, M., et al. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 85:27-37.
69. Sharpless, N.E., et al. 2001. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature. 413:86-91.
70. Chin, L., et al. 1999. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:468-472.
71. Pelengaris, S., Littlewood, T., Khan, M., Elia, G., and Evan, G. 1999. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell. 3:565-577.
72. Pelengaris, S., Khan, M., and Evan, G.I. 2002. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 109:321-334.
73. Jain, M., et al. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:102-104.
74. Felsher, D.W., and Bishop, J.M. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell. 4:199-207.
75. Felsher, D.W., and Bishop, J.M. 1999. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl. Acad. Sci. U. S. A. 96:3940-3944.
76. Fisher, G.H., et al. 2001. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15:3249-3262.